Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer

Ovarian cancer is the 4th largest cause of cancer death in women. Approximately 10–15% of women of childbearing age suffer from endometriosis. Endometriosis is defined by the growth and presence of endometrial tissue (lesions) outside of the uterus. The women with endometriosis also have an increase...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Brunty, Lauren Clower, Brenda Mitchell, Taylor Fleshman, Nadim Bou Zgheib, Nalini Santanam
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	peritoneal fluid FoxP3 EZH2 endometriosis ovarian cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0e1e9013e1f845cb9dd7e534b0ab3b69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e1e9013e1f845cb9dd7e534b0ab3b69
record_format	dspace
spelling	oai:doaj.org-article:0e1e9013e1f845cb9dd7e534b0ab3b692021-12-01T01:08:45ZPeritoneal Modulators of Endometriosis-Associated Ovarian Cancer2234-943X10.3389/fonc.2021.793297https://doaj.org/article/0e1e9013e1f845cb9dd7e534b0ab3b692021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.793297/fullhttps://doaj.org/toc/2234-943XOvarian cancer is the 4th largest cause of cancer death in women. Approximately 10–15% of women of childbearing age suffer from endometriosis. Endometriosis is defined by the growth and presence of endometrial tissue (lesions) outside of the uterus. The women with endometriosis also have an increased presence of peritoneal fluid (PF) that comprises of inflammatory cells, growth factors, cytokines/chemokines, etc. Epidemiological studies have shown that >3% of women with endometriosis develop ovarian cancer (low-grade serous or endometrioid types). Our hypothesis is that the PF from women with endometriosis induces transformative changes in the ovarian cells, leading to ovarian cancer development. PF from women with and without endometriosis was collected after IRB approval and patient consent. IOSE (human normal ovarian epithelial cells) and TOV-21G cells (human ovarian clear cell carcinoma cell line) were treated with various volumes of PF (no endometriosis or endometriosis) for 48 or 96 h and proliferation measured. Expression levels of epigenetic regulators and FoxP3, an inflammatory tumor suppressor, were determined. A Human Cancer Inflammation and Immunity Crosstalk RT2 Profiler PCR array was used to measure changes in cancer related genes in treated cells. Results showed increased growth of TOV-21G cells treated with PF from women with endometriosis versus without endometriosis and compared to IOSE cells. Endo PF treatment induced EZH2, H3K27me3, and FoxP3. The RT2 PCR array of TOV-21G cells treated with endo PF showed upregulation of various inflammatory genes (TLRs, Myd88, etc.). These studies indicate that PF from women with endometriosis can both proliferate and transform ovarian cells and hence this microenvironment plays a major mechanistic role in the progression of endometriosis to ovarian cancer.Sarah BruntyLauren ClowerBrenda MitchellTaylor FleshmanNadim Bou ZgheibNalini SantanamFrontiers Media S.A.articleperitoneal fluidFoxP3EZH2endometriosisovarian cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	peritoneal fluid FoxP3 EZH2 endometriosis ovarian cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	peritoneal fluid FoxP3 EZH2 endometriosis ovarian cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sarah Brunty Lauren Clower Brenda Mitchell Taylor Fleshman Nadim Bou Zgheib Nalini Santanam Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
description	Ovarian cancer is the 4th largest cause of cancer death in women. Approximately 10–15% of women of childbearing age suffer from endometriosis. Endometriosis is defined by the growth and presence of endometrial tissue (lesions) outside of the uterus. The women with endometriosis also have an increased presence of peritoneal fluid (PF) that comprises of inflammatory cells, growth factors, cytokines/chemokines, etc. Epidemiological studies have shown that >3% of women with endometriosis develop ovarian cancer (low-grade serous or endometrioid types). Our hypothesis is that the PF from women with endometriosis induces transformative changes in the ovarian cells, leading to ovarian cancer development. PF from women with and without endometriosis was collected after IRB approval and patient consent. IOSE (human normal ovarian epithelial cells) and TOV-21G cells (human ovarian clear cell carcinoma cell line) were treated with various volumes of PF (no endometriosis or endometriosis) for 48 or 96 h and proliferation measured. Expression levels of epigenetic regulators and FoxP3, an inflammatory tumor suppressor, were determined. A Human Cancer Inflammation and Immunity Crosstalk RT2 Profiler PCR array was used to measure changes in cancer related genes in treated cells. Results showed increased growth of TOV-21G cells treated with PF from women with endometriosis versus without endometriosis and compared to IOSE cells. Endo PF treatment induced EZH2, H3K27me3, and FoxP3. The RT2 PCR array of TOV-21G cells treated with endo PF showed upregulation of various inflammatory genes (TLRs, Myd88, etc.). These studies indicate that PF from women with endometriosis can both proliferate and transform ovarian cells and hence this microenvironment plays a major mechanistic role in the progression of endometriosis to ovarian cancer.
format	article
author	Sarah Brunty Lauren Clower Brenda Mitchell Taylor Fleshman Nadim Bou Zgheib Nalini Santanam
author_facet	Sarah Brunty Lauren Clower Brenda Mitchell Taylor Fleshman Nadim Bou Zgheib Nalini Santanam
author_sort	Sarah Brunty
title	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
title_short	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
title_full	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
title_fullStr	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
title_full_unstemmed	Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
title_sort	peritoneal modulators of endometriosis-associated ovarian cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0e1e9013e1f845cb9dd7e534b0ab3b69
work_keys_str_mv	AT sarahbrunty peritonealmodulatorsofendometriosisassociatedovariancancer AT laurenclower peritonealmodulatorsofendometriosisassociatedovariancancer AT brendamitchell peritonealmodulatorsofendometriosisassociatedovariancancer AT taylorfleshman peritonealmodulatorsofendometriosisassociatedovariancancer AT nadimbouzgheib peritonealmodulatorsofendometriosisassociatedovariancancer AT nalinisantanam peritonealmodulatorsofendometriosisassociatedovariancancer
_version_	1718406004485390336

Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer

Ejemplares similares